Recent

% | $
Quotes you view appear here for quick access.

Dynavax Technologies Corporation Message Board

  • milon5167 milon5167 Feb 25, 2013 8:38 AM Flag

    Do they need another trial?

    Not very much cleared in PR

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 6:02AM Dynavax Technologies receives FDA Complete Response Letter on HEPLISAV Biologic License Application; indication in adults 18-70 years of age cannot be approved without further evaluation of safety in this broad age group (DVAX) 2.97 : Co announced that it received a Complete Response Letter (CRL) from the FDA regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. In the CRL, the FDA specified that the indication in adults 18-70 years of age cannot be approved without further evaluation of safety in this broad age group. The FDA also continues to express concern that novel adjuvants may cause rare autoimmune events. However, the Agency indicated its willingness to continue discussions regarding a more restricted use of HEPLISAV. Co plans to discuss the CRL with the FDA to identify the most expeditious path to approval for HEPLISAV, particularly in adults who may receive the greatest benefit from HEPLISAV. Furthermore, the FDA requested additional data from Dynavax's process validation program and clarifying information on the manufacturing controls and facilities related to the assurance of the quality of the commercial product. Dynavax believes it can provide the information but the exact timeframe for its response cannot be determined until it has met with the Agency. Co plans to meet with the FDA to discuss the steps necessary for potential approval of HEPLISAV and currently believes the meeting can take place within 6 weeks.

 
DVAX
16.08-0.14(-0.86%)May 3 4:00 PMEDT